Lafond Kevin G 4
4 · ZIOPHARM ONCOLOGY INC · Filed Nov 27, 2019
Insider Transaction Report
Form 4
Lafond Kevin G
Vice Pres., Treasurer, & CAO
Transactions
- Sale
Common Stock
2019-11-26$5.25/sh−11,667$61,252→ 85,555 total - Exercise/Conversion
Employee Stock Option (Right to Buy)
2019-11-26−11,667→ 0 totalExercise: $2.85Exp: 2019-12-31→ Common Stock (11,667 underlying) - Exercise/Conversion
Common Stock
2019-11-26$2.85/sh+11,667$33,251→ 97,222 total
Footnotes (2)
- [F1]The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 30, 2019.
- [F2]Fully vested.